Insider Buying: Entrada Therapeutics (NASDAQ:TRDA) Director Buys $29,300.00 in Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Director Bernhardt Zeiher bought 5,000 shares of the company’s stock in a transaction dated Wednesday, May 20th. The shares were acquired at an average cost of $5.86 per share, with a total value of $29,300.00. Following the acquisition, the director directly owned 5,000 shares of the company’s stock, valued at approximately $29,300. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Entrada Therapeutics Trading Up 4.0%

Shares of TRDA opened at $6.56 on Friday. Entrada Therapeutics, Inc. has a 12-month low of $4.93 and a 12-month high of $16.45. The firm has a 50-day moving average price of $11.53 and a 200 day moving average price of $10.85. The firm has a market capitalization of $254.66 million, a P/E ratio of -1.64 and a beta of -0.09.

Entrada Therapeutics (NASDAQ:TRDA) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.11. Entrada Therapeutics had a negative net margin of 2,895.05% and a negative return on equity of 51.22%. The firm had revenue of $0.88 million during the quarter, compared to analyst estimates of $2.92 million. Equities research analysts predict that Entrada Therapeutics, Inc. will post -4.12 earnings per share for the current fiscal year.

Analyst Ratings Changes

TRDA has been the subject of a number of analyst reports. Guggenheim raised shares of Entrada Therapeutics to a “strong-buy” rating in a report on Wednesday, February 11th. HC Wainwright lowered shares of Entrada Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, May 8th. Weiss Ratings reissued a “sell (d)” rating on shares of Entrada Therapeutics in a report on Friday, March 27th. Roth Mkm set a $10.00 price objective on shares of Entrada Therapeutics in a report on Friday, May 8th. Finally, Oppenheimer upped their price objective on shares of Entrada Therapeutics from $21.00 to $23.00 and gave the company an “outperform” rating in a report on Monday, April 6th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $18.25.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of TRDA. Geode Capital Management LLC boosted its stake in Entrada Therapeutics by 7.2% during the second quarter. Geode Capital Management LLC now owns 631,554 shares of the company’s stock worth $4,245,000 after buying an additional 42,479 shares during the period. Rhumbline Advisers boosted its stake in Entrada Therapeutics by 8.3% during the second quarter. Rhumbline Advisers now owns 39,095 shares of the company’s stock worth $263,000 after buying an additional 2,982 shares during the period. American Century Companies Inc. boosted its stake in Entrada Therapeutics by 10.8% during the second quarter. American Century Companies Inc. now owns 75,094 shares of the company’s stock worth $505,000 after buying an additional 7,301 shares during the period. Prudential Financial Inc. boosted its stake in Entrada Therapeutics by 23.4% during the second quarter. Prudential Financial Inc. now owns 28,340 shares of the company’s stock worth $190,000 after buying an additional 5,370 shares during the period. Finally, Invesco Ltd. boosted its stake in Entrada Therapeutics by 34.2% during the second quarter. Invesco Ltd. now owns 22,393 shares of the company’s stock worth $150,000 after buying an additional 5,702 shares during the period. Hedge funds and other institutional investors own 86.39% of the company’s stock.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.